BeOne Medicines' robust financial outlook is driven by zanubrutinib's rapid sales growth and anticipated positive cash flow.

Switching patients with chronic lymphocytic leukemia (CLL) from ibrutinib to zanubrutinib has led to fewer cardiac side effects and a reduced workload for Mohit Narang, MD, managing partner at ...

Zanubrutinib plus venetoclax elicited durable responses in patients with treatment-naïve CLL or SLL and high-risk genetic features.

Zanubrutinib shows durable efficacy in CLL/SLL with 17p deletions, according to 5-year SEQUOIA trial data.

A zanubrutinib, venetoclax, and obinutuzumab triplet achieved deep remissions and high undetectable measurable residual ...

BeiGene , Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Lt ...

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...

Clinical trials help assess whether a new treatment ... Phase III testing continuous versus intermittent treatment with the study drug zanubrutinib for older patients with previously untreated ...

The trial, conducted and funded by GenFleet ... the potential of SLS009 in combination with zanubrutinib to deliver meaningful clinical benefits,” said Angelos Stergiou, MD, ScD h.c., President ...

today announced the presentation of the first interim clinical data from its ongoing open-label, dose-escalation trial of PRT2527, a potent and highly selective CDK9 inhibitor, as monotherapy and ...

Abbreviations: BR, bendamustine plus rituximab; CLL, chronic lymphocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; IGHV, immunoglobulin heavy-chain variable region; SLL ...